Hofseth BioCare ASA reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was NOK 25.28 million compared to NOK 31.04 million a year ago. Revenue was NOK 25.83 million compared to NOK 31.04 million a year ago. Net loss was NOK 28.38 million compared to NOK 24.64 million a year ago. Basic loss per share from continuing operations was NOK 0.08 compared to NOK 0.07 a year ago. Diluted loss per share from continuing operations was NOK 0.08 compared to NOK 0.07 a year ago.
For the six months, sales was NOK 55.49 million compared to NOK 47.77 million a year ago. Revenue was NOK 56.62 million compared to NOK 47.88 million a year ago. Net loss was NOK 64.05 million compared to NOK 51.48 million a year ago. Basic loss per share from continuing operations was NOK 0.18 compared to NOK 0.14 a year ago. Diluted loss per share from continuing operations was NOK 0.18 compared to NOK 0.14 a year ago.